INTERVENTIONAL CARDIOLOGY – NEWS, EVENTS AND TRENDS («Cardiac Interventions Today»)
https://doi.org/10.17802/2306-1278-2015-4-79-82
Abstract
About the Authors
Andrey MURASHKOVSKYRussian Federation
6, Sosnoviy blvd., Kemerovo, 650002
V. I. GANYUKOV
Russian Federation
6, Sosnoviy blvd., Kemerovo, 650002
References
1. O’Gara P. T., Kushner F. G., Ascheim D. D. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 2013; 61: e78–e140.
2. Menees D. S., Peterson E. D., Wang Y. et al. Door-toballoon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 2013; 369: 901–909.
3. Sleeper L. A., Ramanathan K., Picard M. H. et al. SHOCK Investigators. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J. Am. Coll. Cardiol. 2005; 46: 266–273.
4. Ezekowitz J. A., Kaul P., Bakal J. A. et al. Declining inhospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol. 2009; 53: 13–20.
5. Braunwald E., Kloner R. A. Myocardial reperfusion: a double-edged sword? J. Clin. Invest. 1985; 76: 1713–1719.
6. Ong S. B., Samangouei P., Kalkhoran S. B., Hausenloy D. J. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J. Mol. Cell. Cardiol. 2015; 78C: 23–34.
7. Patel M. R., Smalling R. W., Thiele H. et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011; 306: 1329–1337.
8. O’Neill W. W., Schreiber T., Wohns D. H. et al. The current use of Impella 2,5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J. Interv. Cardiol. 2014; 27: 1–11.
9. Breet N. J., van Werkum J. W., Bouman H. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303: 754–762.
10. Price M. J., Berger P. B., Teirstein P. S. et al. GRAVITAS Investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097–1105.
11. Trenk D., Stone G. W., Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug–eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll .Cardiol. 2012; 59: 2159–2164.
12. Collet J. P., Cuisset T., Rangé G. et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 2012; 367: 2100–2109.
13. Gurbel P. A., Erlinge D., Ohman E. M. et al. TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308: 1785–1794.
Review
For citations:
MURASHKOVSKY A., GANYUKOV V.I. INTERVENTIONAL CARDIOLOGY – NEWS, EVENTS AND TRENDS («Cardiac Interventions Today»). Complex Issues of Cardiovascular Diseases. 2015;(4):79-82. (In Russ.) https://doi.org/10.17802/2306-1278-2015-4-79-82